Aegis Capital Believes Akebia Therapeutics (NASDAQ: AKBA) Still Has Room to Grow

By Jason Carr

In a report issued on May 16, Difei Yang from Aegis Capital reiterated a Buy rating on Akebia Therapeutics (NASDAQ: AKBA), with a price target of $25. The company’s shares closed yesterday at $14.43, close to its 52-week high of $15.88.

According to, Yang is a 4-star analyst with an average return of 7.1% and a 45.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Protalix Biotherapeutics, and Spectrum Pharmaceuticals.

Currently, the analyst consensus on Akebia Therapeutics is Strong Buy and the average price target is $23, representing a 59.4% upside.

In a report issued on May 16, H.C. Wainwright also reiterated a Buy rating on the stock with a $25 price target.

The company has a one year high of $15.88 and a one year low of $7. Currently, Akebia Therapeutics has an average volume of 827.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Akebia Therapeutics, Inc. is a biopharmaceutical company which engages in the development of novel proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease. Its lead product candidate, AKB-6548, is in a Phase 2b clinical trial in patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.